GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Pre-Tax Income

SHTDF (Sinopharm Group Co) Pre-Tax Income : $1,927 Mil (TTM As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Sinopharm Group Co's pretax income for the six months ended in Jun. 2024 was $1,047 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was $1,927 Mil. Sinopharm Group Co's pretax margin was 2.58%.

During the past 13 years, Sinopharm Group Co's highest Pretax Margin was 3.65%. The lowest was 2.40%. And the median was 3.32%.


Sinopharm Group Co Pre-Tax Income Historical Data

The historical data trend for Sinopharm Group Co's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Pre-Tax Income Chart

Sinopharm Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,385.29 2,669.55 2,662.74 2,732.72 1,923.02

Sinopharm Group Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,514.72 1,238.03 1,491.01 1,047.11 879.64

Competitive Comparison of Sinopharm Group Co's Pre-Tax Income

For the Medical Distribution subindustry, Sinopharm Group Co's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's Pre-Tax Income Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Pre-Tax Income falls into.


';

Sinopharm Group Co Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Sinopharm Group Co's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=3119.935+0+-414.076+104.11+-77.253
=2,733

Sinopharm Group Co's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=1338.072+0+-187.523+53.682+-157.118
=1,047

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,927 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (OTCPK:SHTDF) Pre-Tax Income Explanation

Sinopharm Group Co's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=1047.113/40625.637
=2.58%

During the past 13 years, Sinopharm Group Co's highest Pretax Margin was 3.65%. The lowest was 2.40%. And the median was 3.32%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research 06-17-2024

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016